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Abstract 
Aims: Recurrence after cancer surgery is a major concern in patients with cancer. Growing evidence 
from preclinical studies has revealed that various anesthetics can influence the immune system in different 
ways. The current study compared the long-term biochemical recurrence of prostate cancer after 
robot-assisted laparoscopic radical prostatectomy (RALP) in terms of selection of anesthetic agent 
between total intravenous anesthesia (TIVA) with propofol/remifentanil and volatile anesthetics (VA) 
with sevoflurane or desflurane/remifentanil.  
Methods: We followed up oncologic outcomes of patients who underwent RALP from two previous 
prospective randomized controlled trials, and the outcomes of those who received TIVA (n = 64) were 
compared with those who received VA (n = 64). The follow-up period lasted from November 2010 to 
March 2019.  
Results: Both TIVA and VA groups showed identical biochemical recurrence-free survivals at all-time 
points after RALP. The following predictive factors of prostate cancer recurrence were determined by 
Cox regression: colloid input [hazard ratio (HR)=1.002, 95% confidence interval (CI): 1.000–1.003; P = 
0.011], initial prostate-specific antigen level (HR=1.025, 95% CI: 1.007–1.044; P = 0.006), and pathological 
tumor stage 3b (HR=4.217, 95% CI:1.207–14.735; P = 0.024), but not the anesthetic agent.  
Conclusions: Our findings demonstrate that both TIVA with propofol/remifentanil and VA with 
sevoflurane or desflurane/remifentanil have comparable effects on oncologic outcomes in patients 
undergoing RALP. 
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Introduction 
A major concern among patients with cancer is 
recurrence after cancer surgery. Aside from several 
well-documented factors that synergistically influence 
the risk of long-term cancer recurrence, recent studies 
have shown that anesthetic agents might affect the 
postoperative prognosis of cancer due to its 
unfavorable effect on the immune system [1, 2], and 
has led to a renewed interest in this field [3].  
Propofol has been reported to exhibit positive 
immunomodulatory effects [3-5], and better survival 
has been reported after cancer surgery with 
propofol-based total intravenous anesthesia (TIVA) 
compared to volatile anesthesia (VA) [6-9]. However, 
other recent studies have yielded different results 
regarding the influence of anesthetic agents on the 
recurrence of breast cancer [10, 11], and different 
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oncologic outcomes have been demonstrated 
depending on the type of cancer [7, 11-14]. 
Currently, the most common malignancy among 
males in the United States is prostate cancer [15], with 
over 160,000 new cases diagnosed in 2018 and almost 
30,000 resultant deaths [16]. Until now, there have 
been no studies of the influence of anesthetic agents 
on the recurrence of prostate cancer. We previously 
published two prospective randomized controlled 
trials, which were conducted to compare 
postoperative nausea and vomiting (PONV) and 
changes in intraocular pressure (IOP) in patients who 
underwent robot-assisted laparoscopic radical 
prostatectomy (RALP) under general anesthesia with 
either propofol-based TIVA or sevoflurane-based VA 
[17, 18]. The patients who participated in these two 
studies underwent RALP 7-9 years ago, providing a 
unique opportunity to assess their cancer status and 
long-term survival.  
Thus, this study aimed to compare the effects of 
VA with sevoflurane or desflurane/remifentanil and 
TIVA with propofol/remifentanil on long-term 
oncologic outcomes, such as biochemical recurrence 
(BCR), in patients with prostate cancer after RALP. 
Materials and Methods 
Study design and participants 
Detailed descriptions of the design of the 
previous trials (PONV and IOP) have been published 
previously [17, 18]. PONV and IOP were randomized 
controlled trials that evaluated and compared the 
effects of VA with sevoflurane or desflurane/ 
remifentanil and TIVA with propofol/remifentanil on 
PONV and the changes of IOP in patients undergoing 
RALP. Sixty-two patients between November 2010 
and May 2011, and 66 patients between May 2011 and 
Mar 2012, were enrolled in the PONV and IOP trials, 
respectively. Additional ethics approvals for the 
follow-up study were obtained from the institutional 
review board (IRB) and hospital research ethics 
committee (Yonsei University Health System, Seoul, 
Korea; IRB protocol No. 4-2019-0313, approved on 23 
May, 2019). The need for informed consent from the 
patients was waived. Patients were followed up from 
November 2010 to March 2019. Additional criterion 
for enrolment in the follow-up study included 
patients who underwent complete surgical excision of 
prostate cancer without any surgical complications. 
Patients with uncertain clinical conditions or 
incomplete follow-up data were excluded. For this 
follow-up study, BCR status, prostate specific antigen 
(PSA) levels, and TNM staging of tumor were 
collected at time points after the original trials.  
Anesthesia protocol 
Premedication was performed with 0.05 mg/kg 
midazolam and 0.2 mg glycopyrrolate 1 hour before 
and immediately before the initiation of anesthesia, 
respectively. Standard monitoring with non-invasive 
blood pressure, electrocardiography, and saturation 
was conducted. Anesthesia was induced with 
propofol and remifentanil in both groups. After loss 
of consciousness, 0.6 mg/kg rocuronium was 
administered to facilitate tracheal intubation. 
Controlled ventilation was performed with 40% 
oxygen in air to maintain end tidal carbon dioxide 
(CO2) at 35-40 mmHg during the surgery, and a 
positive end-expiratory pressure of 5 cm H2O was 
applied. Body temperature was maintained at 36-37°C 
using a forced-air warming system. For continuous 
blood pressure monitoring, 20-G radial artery 
catheterization was performed in all patients. 
In the VA group, anesthesia was induced with 
an intravenous bolus of propofol (1.5 mg/kg) and 
maintained with sevoflurane (1.5–2.5%) or desflurane 
(4–7%). In the TIVA group, propofol was 
administered using a TCI pump (Orchestra® Base 
Primea, Fresenius Vial, France) according to the 
Marsh model. [19] The target plasma concentration of 
propofol was maintained within 2–5 μg/mL. 
Remifentanil was administered to all patients using a 
TCI pump, according to the Minto model [20], and the 
effect-site concentration was adjusted to within 2–5 
ng/mL. The anesthetics administered to each group 
were titrated to maintain mean arterial pressure 
(MAP) and heart rate within 20% of baseline values 
and to provide adequate depth of anesthesia. A 
bispectral index score (BIS) monitor (Aspect A-2000®, 
Aspect Medical System Inc., Newton, MA, USA) was 
used so that the BIS could be maintained within the 
range of 40-60. Additional boluses of 0.15 mg/kg 
rocuronium were administered as needed to maintain 
adequate intraoperative neuromuscular blockade. 
During the operation, CO2 pneumoperitoneum was 
induced to maintain a mean (standard deviation, SD) 
intra-abdominal pressure of 15 (5) mmHg using a CO2 
insufflator in a 30° Trendelenburg position. The 
Trendelenburg angle was accurately adjusted by the 
operating table controller, which showed the tilted 
angle in numbers. 
All patients received 0.3 mg ramosetron 
intravenously 20 minutes before the end of surgery, 
and postoperative pain was controlled using 
intravenous patient-controlled analgesia (PCA), 
consisting of 20 μg/kg fentanyl mixed with normal 
saline to a total volume of 100 ml, administered at a 
basal rate of 2 ml/h, with a bolus dose of 0.5 ml and a 
15-min lockout time. At the end of surgery, reversal of 
neuromuscular blockade was performed with 50 
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μg/kg neostigmine and 10 μg/kg glycopyrrolate 
intravenously. After extubation and when fully 
awake, the patients were transported to the 
post-anesthesia care unit.  
Statistical Analysis 
The primary endpoint of the study was the 
effects of VA with sevoflurane or desflurane/ 
remifentanil and TIVA with propofol/remifentanil on 
BCR in patients after RALP. Patients were followed 
up with serum PSA tests at 3-month intervals for the 
first 2 years, at 6-month intervals for the next 3 years, 
and annually thereafter. BCR was defined as two 
consecutive rises in serum PSA levels ≥0.2 ng/ml at 
any time postoperatively. Continuous variables are 
presented as means (SD), and categorical variables are 
presented as numbers of patients (percentages). 
Continuous variables were compared using 
independent t-tests, and categorical variables were 
compared using the chi-square test or Fisher’s exact 
test. Kaplan-Meier curves were calculated based on 
the occurrence of BCR for each period (12, 24, 36 
months, and overall), and the groups were compared 
using the log-rank test. Cox proportional hazard 
regression was performed to identify associated 
independent factors, and the results are presented as 
hazard ratios (HRs) and 95% confidence intervals 
(CIs). SAS version 9.4 (SAS Institute Inc., Cary, NC, 
USA) was used for all statistical analyses. A p-value < 
0.05 was considered statistically significant. 
 Results 
Out of 128 patients who were enrolled in both 
prospective randomized trials (62 and 66 eligible 
patients in the PONV and IOP trials, respectively), 
two patients with follow-up loss were excluded from 
the VA group. The final sample for analysis included 
126 patients who had been assigned to either the 
TIVA (n = 64) or the VA (n = 62) group (Figure 1). 
Table 1 shows the distribution of demographics 
and perioperative variables in both groups. As is 
expected from the randomized study design, baseline 
characteristics of the two groups were comparable. In 
the VA group, two volatile agents were used: 31 
patients received sevoflurane and 31 patients received 
desflurane, with BCR observed in 13 patients (42%) 
receiving sevoflurane and in 15 patients (48%) 
receiving desflurane. There was no significant 
difference in the incidence of BCR between the two 
volatile agents in the VA group (P = 0.799). 
 
 
 
Figure 1. Consort flow diagram. PONV = postoperative nausea and vomiting; IOP = intraocular pressure; TIVA = total intravenous anesthesia; VA = volatile anesthesia. 
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Figure 2. BCR-free survival between the TIVA and VA groups at any follow-up point after RALP. IOP = intraocular pressure; TIVA = total intravenous anesthesia; VA = volatile 
anesthesia; BCR = biochemical recurrence. 
 
Table 1. Demographics and perioperative variables. 
Variables VA group  
(n = 62) 
TIVA group  
(n = 64) 
P value 
Age, years 62.9 (7.1) 63.9 (8.0) 0.497 
Height, m2 168.1 (5.2) 167.9 (6.9) 0.776 
Weight, kg 69.3 (10.3) 69.1 (9.4) 0.920 
ASA physical status   0.702 
I 26 (42%) 29 (45%)  
II 36 (58%) 35 (55%)  
Sevoflurane/Desflurane, n 31/31   
Anesthesia time, min  190.4 (40.4) 192.1 (45.2) 0.821 
Pneumoperitoneum time, min 114.7 (36.3) 118.9 (40.8) 0.546 
Intraoperative input & Output 
Total fluid, mL 1731 (532) 1669 (683) 0.573 
Colloid, mL 146 (258) 107 (186) 0.399 
Blood loss, mL 442 (281) 375 (220) 0.193 
Urine output, mL 167 (121) 224 (177) 0.069 
Values are presented as means (SD) or numbers of patients (%). VA, volatile 
anesthesia; TIVA, total intravenous anesthesia; ASA, American Society of 
Anesthesiologists. 
 
The incidences of BCR and pathological 
variables are presented in Table 2. The number of 
patients who presented BCR was 28 (45.2%) in the VA 
group and 25 (39.1%) in the TIVA group, with no 
significant difference between the two groups. 
Similarly, the number of patients with positive 
radiographic progression did not differ between the 
two groups. Initial PSA levels, Gleason score, surgical 
margin status, pathological tumor stage, and lymph 
node metastasis were also similar in both groups. 
BCR-free survival was identical between the VA 
and TIVA groups at any follow-up point after RALP 
(Figure 2).  
Cox regression identified significant predictors 
of prostate cancer recurrence after RALP as colloid 
input (HR=1.002, 95% CI:1.000-1.003; P = 0.011), initial 
PSA level (HR=1.025, 95% CI:1.007-1.044; P = 0.006), 
and pathological tumor stage 3b (HR=4.217, 95% 
CI:1.207-14.735; P = 0.024), but there was no 
dependence found on different general anesthetics 
(Table 3).  
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Table 2. Incidence of recurrence and pathological variables. 
Variables VA group  
(n = 62) 
TIVA group  
(n = 64) 
p-value 
BCR 28 (45.2%) 25 (39.1%) 0.481 
Positive radiographic 
progression 
5 (8.1%) 3 (4.7%) 0.488 
Initial PSA level, ng/mL 12.8 (12.2) 14.2 (18.0) 0.606 
Gleason score   0.474 
6 18 (29.0%) 24 (37.5%)  
7 30 (48.4%) 30 (46.9%)  
>=8 14 (22.6%) 10 (15.6%)  
Surgical margin status   0.722 
negative 30 (48.4%) 33 (51.6%)  
positive 32 (51.6%) 31 (48.4%)  
Pathological Tumor stage    0.575 
2 30 (48.4%) 37 (57.8%)  
3a 27 (43.6%) 23 (35.9%)  
3b 5 (8.1%) 4 (6.3%)  
Lymph node metastasis    > 0.999 
negative 60 (96.8%) 61 (95.3%)  
positive 2 (3.2%) 3 (4.7%)  
Values are presented as means (SD) or numbers of patients (%). VA, volatile 
anesthesia; TIVA, total intravenous anesthesia; BCR, biochemical recurrence; PSA, 
prostate specific antigen. 
 
Table 3. Univariate and multivariate analysis of risk factors for 
BCR after RALP (n = 126). 
Variables   Univariate  Multivariate 
HR (95% CI) P value HR (95% CI) P 
value 
Group 0.940 (0.548 – 1.613) 0.823 1.227 (0.660 – 2.283) 0.518 
Age, year 1.002 (0.968 – 1.038) 0.904   
Height, m2 0.969 (0.924 – 1.017) 0.204   
Weight, kg 1.005 (0.977 – 1.033) 0.741   
ASA physical 
status 
    
I 1    
II 1.171 (0.680 – 2.018) 0.570   
Anesthesia time, 
min  
0.994 (0.988 – 1.001) 0.082   
Pneumoperiton
eum time, min 
0.993 (0.985 – 1.000) 0.053   
Intraoperative input & Output 
Fluid input, mL  1.000 (1.000 – 1.001) 0.677   
Colloid input, 
mL 
1.002 (1.001 – 1.003) 0.003 1.002 (1.000 – 1.003) 0.011* 
Urine output, 
mL  
1.001 (1.000 – 1.002) 0.331   
Blood loss, mL  1.001 (1.000 – 1.002) 0.412   
Initial PSA level, 
ng/mL 
1.028 (1.015 – 1.041) <0.001 1.025 (1.007 – 1.044) 0.006* 
Gleason score     
6 1    
7 3.120 (1.353 – 7.194) 0.008 1.053 (0.313 – 3.539) 0.934 
>=8 8.182 (3.424 – 19.551) <0.001 1.630 (0.444 – 5.982) 0.461 
Surgical margin status 
Negative 1    
Positive 2.967 (1.648 – 5.341) <0.001 1.806 (0.893 – 3.653) 0.100 
Pathological 
Tumor stage 
    
2 1    
3a 4.079 (2.159 – 7.704) <0.001 2.262 (0.855 – 5.987) 0.100 
3b 8.388 (3.477 – 20.239) <0.001 4.217 (1.207 – 14.735) 0.024* 
Lymph node 
metastasis 
    
Negative 1    
Positive 3.073 (1.100 – 8.587) 0.032 0.607 (0.154 – 2.395) 0.476 
BCR, biochemical recurrence; RALP, robot-assisted radical prostatectomy; HR, 
hazard ratio; CI, confidence interval; VA, Volatile anesthesia; TIVA, total 
intravenous anesthesia; ASA, American Society of Anesthesiologists; PSA, prostate 
specific antigen. 
 
Discussion 
This is the first study to compare the effects of 
VA with sevoflurane or desflurane/remifentanil and 
TIVA with propofol/remifentanil on oncologic 
outcomes in patients after RALP. An additional 
strength of this study is that we analyzed 7-9 years of 
outcomes in patients who were randomly assigned to 
either the VA or TIVA groups.  
It has been well documented that metabolic and 
neuroendocrine changes due to perioperative stress 
cause significant depression of cell-mediated 
immunity. Inevitably, this can bring out micro-seed 
tumor cells during surgery which can avoid host 
immune surveillance, eventually resulting in tumor 
recurrence [8]. In addition, there is growing evidence 
from preclinical studies to show that volatile 
anesthetic agents may alter immune processes 
through the attenuation of NK cell cytotoxicity [21], 
cytokine release, and chemotaxis of immune cells [22, 
23]. Moreover, several studies have shown that 
volatile anesthetic agents can have a direct effect on 
tumor cells and induce mitogenesis, angiogenesis, 
and metastasis of tumors, which is associated with 
increased expression of insulin-like growth factor, 
vascular endothelial growth factor, and 
hypoxia-inducible factor (HIF) protein [24-27].  
In contrast, propofol appears to increase the 
activity of cytotoxic T-lymphocytes [28] and not 
suppress NK cell activity in vitro [3]. In addition, 
propofol directly prevents HIF activation [29], and 
may exert anti-tumor effects mediated through 
inhibition of the cyclooxygenase pathway [30]. It has 
also been reported that propofol has an inhibitory 
effect on the sympathetic nervous system, which 
attenuates catecholamine release [31]. The nervous 
system is a primary actor in early and late cancer 
development. Many cancers (e.g., colon and prostate) 
present a specific growth pattern called “perineural 
invasion” which is driven by neurons [32]. The 
growth of some cancers, such as prostate cancer, 
pancreatic cancer, and breast cancer, is associated 
with “neurogenesis” and abundant infiltration of the 
tumor by the autonomic nervous system [33]. The 
prostate has a sympathetic nerve supply that is 5 or 6 
times greater than that of the other chromaffin organs, 
making it particularly susceptible to these effects [34]. 
The stress response results from stimulation of the 
sympathetic nervous system, which enhances tumor 
growth through immunosuppression and beta- 
adrenergic stimulation of tumor cells [33]. In animal 
studies, sympathectomy has been reported to slow the 
progression of cancer, and human retrospective data 
have indicated lower rates of recurrence and mortality 
among patients with cancer taking beta-blockers [35]. 
Thus, we envisaged favorable long-term oncologic 
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outcomes in the TIVA group owing to the 
comparatively safer effects of propofol, such as the 
relative preservation of cellular immunity and 
inhibition of sympathetic activity. However, our 
results showed no difference in the rate of recurrence 
after RALP between the VA and TIVA groups. In 
addition, there was no difference between these 
groups after subgroup analysis of volatile anesthetics.  
There have been many clinical studies on this 
topic, but these were retrospective studies. Previous 
studies in patients with colorectal and esophageal 
cancer showed better prognosis in patients receiving 
TIVA with propofol [10-12]. However, in studies of 
lung and breast cancer surgery, there were no 
differences in oncologic outcomes, which is consistent 
with the current results [8,9,14,36]. It has been shown 
that expression of catecholamine associated with 
stress, such as norepinephrine, promotes cell 
migration in colon, prostate, ovarian, and breast 
cancer cells [37]. Similarly, according to the type of 
cancer, volatile anesthetics or propofol may have 
markedly different influences on oncologic outcomes. 
To date, however, no studies have been conducted to 
compare the effects of volatile anesthetics or propofol 
on oncological outcomes according to the various 
cancer cell types. Therefore, more studies are required 
in this area. 
While the impact of opioid use on recurrence is 
debatable, opioids such as fentanyl and morphine 
have been reported to promote poor oncologic 
outcomes in terms of immunity and angiogenesis [38, 
39]. Regarding the unfavorable tumor 
microenvironment caused by opioids, intraoperative 
infusion of remifentanil may have affected the 
recurrence rate after RALP in our study. Although a 
previous study provided evidence that a low dose 
infusion of remifentanil does not affect cellular 
immunity status [40], this study targeted only healthy 
volunteers and did not include patients with reduced 
immunity or immunocompromised patients, such as 
patients with cancer. The dose was also lower than 
that typically administered during surgery. In animal 
models of breast cancer, early administration of 
morphine did not affect the growth of cancer cells, but 
morphine administered after cancer progression 
reduced the survival rate, as morphine directly acts on 
µ-opioid receptors (MOR) expressed in the tumor, 
thereby promoting the growth of cancer cells [41]. In 
recent studies, it has been shown that the increased 
expression of MOR in patients with cancer is 
associated with worse prognosis. A recent mediation 
study showed that twice as much MOR is expressed 
in the tissues of patients with metastatic lung cancer 
compared to patients with lung cancer [42]. In 
addition, a study of patients with advanced prostate 
cancer indicated a significantly shorter progression- 
free survival in patients with higher MOR expression 
in cancer tissues and greater morphine requirements 
after cancer diagnosis [43]. Considering the impact of 
opioids on cancer growth, the continuous infusion of 
remifentanil in both groups could have been another 
confounding factor for the negative outcomes in the 
current study.  
Finally, in previous reports that showed 
favorable effects of propofol on oncologic outcomes, 
most cases were combined with epidural analgesia, 
except one that involved patients undergoing 
gastrectomy [8, 9, 13, 14, 36]. However, in recent 
studies which did not apply regional or neuraxial 
analgesia, there was no benefit of propofol-based 
TIVA for long-term oncologic outcomes after 
non-small cell lung cancer and breast cancer surgery 
[10-12]. The majority of studies which showed better 
oncologic outcomes associated with propofol-based 
TIVA applied regional or neuraxial analgesia for pain 
control, and consequently, small dose of opioids were 
used during surgery. Opioids may therefore be a 
significant confounding factor for confirming the 
influence of propofol on oncologic outcomes. Thus, 
there are many difficulties in obtaining accurate 
results, and well-controlled prospective clinical 
studies of these confounding variables are required.  
There are several limitations to the current 
study. First, this is a retrospective study. However, 
the selection bias may be negligible because only 
randomly assigned patients were included and there 
was marginal difference in the surgical techniques 
owing to the relatively short study period from 
November 2010 to March 2012. Second, our sample 
size was limited by the size of the original PONV and 
IOP trials, and follow-up data were not available for 2 
patients. Our analysis was thus restricted to 64 
patients in the TIVA group and 62 patients in the VA 
group. Although it may seem that the sample size is 
limited, we consider this to be a sufficiently influential 
outcome, since this study was based on data from a 
period of 7-9 years over which patients were enrolled 
and randomly assigned. Third, the volatile agents in 
the two original trials were different (desflurane in the 
PONV trial and sevoflurane in the IOP trial). 
However, no differences were found between the two 
volatile anesthetics following subgroup analysis. 
Finally, anesthetic induction was also performed 
using a bolus injection of propofol in the VA group. 
However, the influence of small amounts of propofol 
during the induction period in the VA group is 
considered to be insignificant based on the primary 
outcomes of previous studies where intraoperative 
IOP and PONV were significantly better in the TIVA 
group.  
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Conclusions 
This study was the first report on the long-term 
follow-up of prostate cancer recurrence after RALP 
under TIVA with propofol/remifentanil and VA with 
sevoflurane or desflurane/remifentanil. Our findings 
demonstrate that both TIVA with propofol/ 
remifentanil and VA with sevoflurane or desflurane/ 
remifentanil have comparable effects on oncologic 
outcomes in patients undergoing RALP. Additionally, 
we believe that the type of cancer should be 
considered as a potential factor in the clinical decision 
of the choice of anesthetic for cancer surgery. 
However, for further validation of our findings, 
additional prospective trials should be undertaken 
that will closely monitor and control the influence of 
opioids on oncologic outcomes.  
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